Xeris Biopharma Holdings (XERS) Profit After Tax (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported Profit After Tax for 7 consecutive years, with -$31.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Profit After Tax fell 1513.12% year-over-year to -$31.1 million; the trailing twelve-month figure through Jun 2026 stood at -$17.2 million (up 46.36% YoY), and the FY2025 full-year result was $554000.0, up 101.01% from the prior year.
• Profit After Tax eased to -$31.1 million in Q2 2026 per XERS's latest filing, from $2.2 million in the prior quarter.
• Across five years, Profit After Tax topped out at $11.1 million in Q4 2025 and bottomed at -$33.7 million in Q1 2022.
• Historically, Profit After Tax has averaged -$13.3 million across 5 years, with a median of -$14.2 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Profit After Tax soared 316.72% in 2025, then tumbled 1513.12% in 2026.
• Over 5 years, Profit After Tax stood at -$12.9 million in 2022, then dropped by 3.41% to -$13.4 million in 2023, then soared by 61.74% to -$5.1 million in 2024, then jumped by 316.72% to $11.1 million in 2025, then tumbled by 380.67% to -$31.1 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$31.1 million, $2.2 million, and $11.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.